Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Новые представления о гастропатии, ассоциированной с применением нестероидных противовоспалительных препаратов
Новые представления о гастропатии, ассоциированной с применением нестероидных противовоспалительных препаратов
Маев И.В., Андреев Д.Н., Дичева Д.Т., Жиляев Е.В. Новые представления о гастропатии, ассоциированной с применением нестероидных противовоспалительных препаратов. Consilium Medicum. 2017; 19 (8): 110–115. DOI: 10.26442/2075-1753_19.8.110-115
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Более 30 млн человек ежедневно принимают нестероидные противовоспалительные препараты (НПВП). Регулярное применение НПВП сопряжено с целым рядом побочных явлений и рисков, лидером которых являются воспалительные, эрозивно-язвенные изменения слизистой оболочки желудочно-кишечного тракта (ЖКТ). НПВП могут индуцировать поражение ЖКТ на всем его протяжении от пищевода до прямой кишки, однако поражение верхних отделов ЖКТ развивается в 6 раз чаще. НПВП-гастропатии являются актуальной проблемой современной клинической медицины, учитывая высокую распространенность и частоту осложнений. На риск развития НПВП-гастропатий влияет ряд факторов, включая возраст пациента, инфицирование Helicobacter pylori, наличие осложненного течения заболеваний ЖКТ в анамнезе, сопутствующее применение ряда других лекарственных препаратов. На данный момент наиболее распространенной из применяемых стратегий профилактики НПВП-гастропатии являются комбинированная терапия НПВП с ингибитором протонной помпы, а также применение селективных ингибиторов циклооксигеназы-2. Внедрение в клиническую практику нового гастропротективного препарата с доказанным эффектом – ребамипида – открывает новые перспективы ведения этой непростой группы пациентов.
Ключевые слова: нестероидные противовоспалительные препараты, гастропатия, циклооксигеназа, Helicobacter pylori, ингибиторы протонной помпы, ребамипид.
Key words: nonsteroidal anti-inflammatory drugs, gastropathy, cyclooxygenase, Helicobacter pylori, proton pump inhibitors, rebamipide.
Ключевые слова: нестероидные противовоспалительные препараты, гастропатия, циклооксигеназа, Helicobacter pylori, ингибиторы протонной помпы, ребамипид.
________________________________________________
Key words: nonsteroidal anti-inflammatory drugs, gastropathy, cyclooxygenase, Helicobacter pylori, proton pump inhibitors, rebamipide.
Полный текст
Список литературы
1. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000; 7 (2): 115–21.
2. Маев И.В., Самсонов А.А., Андреев Д.Н. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обоснованные подходы к профилактике и терапии. Фарматека. 2016; 2: 49–54. / Maev I.V., Samsonov A.A., Andreev D.N. Gastropatii, indutsirovannye nesteroidnymi protivovospalitel'nymi sredstvami: patogeneticheski obosnovannye podkhody k profilaktike i terapii. Farmateka. 2016; 2: 49–54. [in Russian]
3. Tannenbaum H, Bombardier C, Davis P, Russel AS. An Evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006; 33: 140–57.
4. Lanas A, Chan FK. Peptic ulcer disease. Lancet 2017 Feb 23. pii: S0140-6736(16)32404-7.
5. Lanas A, Perez-Aisa MA, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100 (8): 1685–93.
6. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it – can we stop it? Arch Intern Med 1986; 146 (6): 1075–6.
7. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 3): S3.
8. Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol 2016; 10 (6): 723–33.
9. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82 (11): 1153–8.
10. Lanas Á, Carrera-Lasfuentes P, Arguedas Y et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13 (5): 906–12.e2.
11. Lewis SC, Langman MJ, Laporte JR et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54 (3): 320–6.
12. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46.
13. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382 (9894): 769–79.
14. Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol 2014; 12 (4): 398–413.
15. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М.: ГЭОТАР-Медиа, 2015. / Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
16. DeRuiter J. Non-steroidal antiinflammatory drugs (NSAIDS). Principles of Drug Action 2002; 2: 1–25.
17. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-nflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 121–32.
18. Zidar N, Odar K, Glavac D et al. Cyclooxygenase in normal human tissues – is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? Cell Mol Med B 2009; 13 (9): 3753–63.
19. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6 (3): 489–504.
20. Mitchell JA, Akarasereenont P, Thiemermann C et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90 (24): 11693–7.
21. Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci 2005; 50 (1): S16–S23.
22. Konturek SJ, Konturek PC, Pawlik T et al. Duodenal mucosal protection by bicarbonate secretion and its mechanisms. J Physiol Pharmacol 2004; 55: 5–17.
23. Свинцицкий А.С. НПВП гастродуоденопатии у больных остеоартрозом: особенности диагностики, профилактики и лечения. Научно-практическая ревматология. 2002; 3: 26–31. / Svintsitskii A.S. NPVP gastroduodenopatii u bol'nykh osteoartrozom: osobennosti diagnostiki, profilaktiki i lecheniia. Nauchno-prakticheskaia revmatologiia. 2002; 3: 26–31. [in Russian]
24. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34 (6): 742–7.
25. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992; 16 (3): 227–40.
26. Andrews FJ, Malcontenti-Wilson C, O’Brien PE. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994; 266 (4, part 1): G657–G664.
27. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109 (4): 1173–80.
28. Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть I). Клин. мед. 2000; 3: 4–9. / Nasonov E.L., Karateev A.E. Porazheniia zheludka, sviazannye s priemom nesteroidnykh protivovospalitel'nykh preparatov (chast' I). Klin. med. 2000; 3: 4–9. [in Russian].
29. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-steroidal anti- inflammatory drug-gastropathy. Digest Liver Dis 2001; 33 (Suppl. 2): S35.
30. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа, 2016. / Maev I.V., Samsonov A.A., Andreev D.N. Infektsiia Helicobacter pylori. M.: GEOTAR-Media, 2016. [in Russian].
31. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359 (9300): 14–22.
32. Lim YJ, Hong SJ. Helicobacter pylori infection in nonsteroidal anti-infl ammatory drug users. Korean J Gastroenterol 2014; 64 (2): 70–5.
33. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
34. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology, Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
35. Laine L. The role of proton pump inhibitors in NSAID – associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Dis 2003; 3 (4): S30–S39.
36. Micklewright R, Lane S, Linley W et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003; 17 (3): 321–32.
37. Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. Ther Clin Risk Management 2008; 4 (5): 983–97.
38. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
39. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343 (21): 1520–8.
40. Schwartz J, Dallob A, Larson P et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008; 48 (6): 745–54.
41. Chan F, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173–9.
42. Goldstein J, Eisen G, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 3–13.
43. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiology 2005; 71 (7–8): 461–70.
44. Nguyen A, Chaiton A. Cyclooxygenase (COX-2) selective inhibitors: any better than NSAIDs? Can Fam Physician 2001; 47: 1398–400.
45. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs – nice or necessary? Rev Gastroenterol Dis 2004; 4 (Suppl. 4): S33–S41.
46. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411e18.
47. Koch M. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol 1999; 31 (1): S54–S62.
48. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241–9.
49. Graham Y, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119 (4): 257–62.
50. Iinuma S, Naito Y, Yoshikawa T et al. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci 1998; 43 (Suppl. 9): 35S–39S.
51. Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41 (6): 1139–44.
52. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Exp Rev Gastroenterol Hepatol 2010; 4 (3): 261–70.
53. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
54. Kim JH, Park SH, Cho CS et al. Preventive efficacy and safety of rebamipid in NSAD-indused toxicity. Gut Liver 2014; 8 (4): 371–79.
55. Park SH, Cho CS, Lee OY et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr 2007; 40 (2): 148–55.
56. Tozawa K, Oshima T, Okugawa T et al. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig Dis Sci 2014; 59 (8): 1885–90.
57. Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci 2008; 106 (3): 469–77.
2. Maev I.V., Samsonov A.A., Andreev D.N. Gastropatii, indutsirovannye nesteroidnymi protivovospalitel'nymi sredstvami: patogeneticheski obosnovannye podkhody k profilaktike i terapii. Farmateka. 2016; 2: 49–54. [in Russian]
3. Tannenbaum H, Bombardier C, Davis P, Russel AS. An Evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006; 33: 140–57.
4. Lanas A, Chan FK. Peptic ulcer disease. Lancet 2017 Feb 23. pii: S0140-6736(16)32404-7.
5. Lanas A, Perez-Aisa MA, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100 (8): 1685–93.
6. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it – can we stop it? Arch Intern Med 1986; 146 (6): 1075–6.
7. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 3): S3.
8. Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol 2016; 10 (6): 723–33.
9. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82 (11): 1153–8.
10. Lanas Á, Carrera-Lasfuentes P, Arguedas Y et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13 (5): 906–12.e2.
11. Lewis SC, Langman MJ, Laporte JR et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54 (3): 320–6.
12. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46.
13. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382 (9894): 769–79.
14. Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol 2014; 12 (4): 398–413.
15. Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
16. DeRuiter J. Non-steroidal antiinflammatory drugs (NSAIDS). Principles of Drug Action 2002; 2: 1–25.
17. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-nflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 121–32.
18. Zidar N, Odar K, Glavac D et al. Cyclooxygenase in normal human tissues – is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? Cell Mol Med B 2009; 13 (9): 3753–63.
19. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6 (3): 489–504.
20. Mitchell JA, Akarasereenont P, Thiemermann C et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90 (24): 11693–7.
21. Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci 2005; 50 (1): S16–S23.
22. Konturek SJ, Konturek PC, Pawlik T et al. Duodenal mucosal protection by bicarbonate secretion and its mechanisms. J Physiol Pharmacol 2004; 55: 5–17.
23. Svintsitskii A.S. NPVP gastroduodenopatii u bol'nykh osteoartrozom: osobennosti diagnostiki, profilaktiki i lecheniia. Nauchno-prakticheskaia revmatologiia. 2002; 3: 26–31. [in Russian]
24. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34 (6): 742–7.
25. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992; 16 (3): 227–40.
26. Andrews FJ, Malcontenti-Wilson C, O’Brien PE. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994; 266 (4, part 1): G657–G664.
27. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109 (4): 1173–80.
28. Nasonov E.L., Karateev A.E. Porazheniia zheludka, sviazannye s priemom nesteroidnykh protivovospalitel'nykh preparatov (chast' I). Klin. med. 2000; 3: 4–9. [in Russian].
29. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-steroidal anti- inflammatory drug-gastropathy. Digest Liver Dis 2001; 33 (Suppl. 2): S35.
30. Maev I.V., Samsonov A.A., Andreev D.N. Infektsiia Helicobacter pylori. M.: GEOTAR-Media, 2016. [in Russian].
31. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359 (9300): 14–22.
32. Lim YJ, Hong SJ. Helicobacter pylori infection in nonsteroidal anti-infl ammatory drug users. Korean J Gastroenterol 2014; 64 (2): 70–5.
33. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
34. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology, Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
35. Laine L. The role of proton pump inhibitors in NSAID – associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Dis 2003; 3 (4): S30–S39.
36. Micklewright R, Lane S, Linley W et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003; 17 (3): 321–32.
37. Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. Ther Clin Risk Management 2008; 4 (5): 983–97.
38. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
39. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343 (21): 1520–8.
40. Schwartz J, Dallob A, Larson P et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008; 48 (6): 745–54.
41. Chan F, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173–9.
42. Goldstein J, Eisen G, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 3–13.
43. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiology 2005; 71 (7–8): 461–70.
44. Nguyen A, Chaiton A. Cyclooxygenase (COX-2) selective inhibitors: any better than NSAIDs? Can Fam Physician 2001; 47: 1398–400.
45. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs – nice or necessary? Rev Gastroenterol Dis 2004; 4 (Suppl. 4): S33–S41.
46. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411e18.
47. Koch M. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol 1999; 31 (1): S54–S62.
48. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241–9.
49. Graham Y, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119 (4): 257–62.
50. Iinuma S, Naito Y, Yoshikawa T et al. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci 1998; 43 (Suppl. 9): 35S–39S.
51. Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41 (6): 1139–44.
52. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Exp Rev Gastroenterol Hepatol 2010; 4 (3): 261–70.
53. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
54. Kim JH, Park SH, Cho CS et al. Preventive efficacy and safety of rebamipid in NSAD-indused toxicity. Gut Liver 2014; 8 (4): 371–79.
55. Park SH, Cho CS, Lee OY et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr 2007; 40 (2): 148–55.
56. Tozawa K, Oshima T, Okugawa T et al. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig Dis Sci 2014; 59 (8): 1885–90.
57. Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci 2008; 106 (3): 469–77.
2. Маев И.В., Самсонов А.А., Андреев Д.Н. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обоснованные подходы к профилактике и терапии. Фарматека. 2016; 2: 49–54. / Maev I.V., Samsonov A.A., Andreev D.N. Gastropatii, indutsirovannye nesteroidnymi protivovospalitel'nymi sredstvami: patogeneticheski obosnovannye podkhody k profilaktike i terapii. Farmateka. 2016; 2: 49–54. [in Russian]
3. Tannenbaum H, Bombardier C, Davis P, Russel AS. An Evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006; 33: 140–57.
4. Lanas A, Chan FK. Peptic ulcer disease. Lancet 2017 Feb 23. pii: S0140-6736(16)32404-7.
5. Lanas A, Perez-Aisa MA, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100 (8): 1685–93.
6. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it – can we stop it? Arch Intern Med 1986; 146 (6): 1075–6.
7. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 3): S3.
8. Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol 2016; 10 (6): 723–33.
9. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82 (11): 1153–8.
10. Lanas Á, Carrera-Lasfuentes P, Arguedas Y et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13 (5): 906–12.e2.
11. Lewis SC, Langman MJ, Laporte JR et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54 (3): 320–6.
12. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46.
13. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382 (9894): 769–79.
14. Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol 2014; 12 (4): 398–413.
15. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М.: ГЭОТАР-Медиа, 2015. / Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
16. DeRuiter J. Non-steroidal antiinflammatory drugs (NSAIDS). Principles of Drug Action 2002; 2: 1–25.
17. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-nflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 121–32.
18. Zidar N, Odar K, Glavac D et al. Cyclooxygenase in normal human tissues – is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? Cell Mol Med B 2009; 13 (9): 3753–63.
19. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6 (3): 489–504.
20. Mitchell JA, Akarasereenont P, Thiemermann C et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90 (24): 11693–7.
21. Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci 2005; 50 (1): S16–S23.
22. Konturek SJ, Konturek PC, Pawlik T et al. Duodenal mucosal protection by bicarbonate secretion and its mechanisms. J Physiol Pharmacol 2004; 55: 5–17.
23. Свинцицкий А.С. НПВП гастродуоденопатии у больных остеоартрозом: особенности диагностики, профилактики и лечения. Научно-практическая ревматология. 2002; 3: 26–31. / Svintsitskii A.S. NPVP gastroduodenopatii u bol'nykh osteoartrozom: osobennosti diagnostiki, profilaktiki i lecheniia. Nauchno-prakticheskaia revmatologiia. 2002; 3: 26–31. [in Russian]
24. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34 (6): 742–7.
25. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992; 16 (3): 227–40.
26. Andrews FJ, Malcontenti-Wilson C, O’Brien PE. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994; 266 (4, part 1): G657–G664.
27. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109 (4): 1173–80.
28. Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть I). Клин. мед. 2000; 3: 4–9. / Nasonov E.L., Karateev A.E. Porazheniia zheludka, sviazannye s priemom nesteroidnykh protivovospalitel'nykh preparatov (chast' I). Klin. med. 2000; 3: 4–9. [in Russian].
29. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-steroidal anti- inflammatory drug-gastropathy. Digest Liver Dis 2001; 33 (Suppl. 2): S35.
30. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа, 2016. / Maev I.V., Samsonov A.A., Andreev D.N. Infektsiia Helicobacter pylori. M.: GEOTAR-Media, 2016. [in Russian].
31. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359 (9300): 14–22.
32. Lim YJ, Hong SJ. Helicobacter pylori infection in nonsteroidal anti-infl ammatory drug users. Korean J Gastroenterol 2014; 64 (2): 70–5.
33. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
34. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology, Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
35. Laine L. The role of proton pump inhibitors in NSAID – associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Dis 2003; 3 (4): S30–S39.
36. Micklewright R, Lane S, Linley W et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003; 17 (3): 321–32.
37. Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. Ther Clin Risk Management 2008; 4 (5): 983–97.
38. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
39. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343 (21): 1520–8.
40. Schwartz J, Dallob A, Larson P et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008; 48 (6): 745–54.
41. Chan F, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173–9.
42. Goldstein J, Eisen G, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 3–13.
43. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiology 2005; 71 (7–8): 461–70.
44. Nguyen A, Chaiton A. Cyclooxygenase (COX-2) selective inhibitors: any better than NSAIDs? Can Fam Physician 2001; 47: 1398–400.
45. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs – nice or necessary? Rev Gastroenterol Dis 2004; 4 (Suppl. 4): S33–S41.
46. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411e18.
47. Koch M. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol 1999; 31 (1): S54–S62.
48. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241–9.
49. Graham Y, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119 (4): 257–62.
50. Iinuma S, Naito Y, Yoshikawa T et al. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci 1998; 43 (Suppl. 9): 35S–39S.
51. Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41 (6): 1139–44.
52. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Exp Rev Gastroenterol Hepatol 2010; 4 (3): 261–70.
53. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
54. Kim JH, Park SH, Cho CS et al. Preventive efficacy and safety of rebamipid in NSAD-indused toxicity. Gut Liver 2014; 8 (4): 371–79.
55. Park SH, Cho CS, Lee OY et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr 2007; 40 (2): 148–55.
56. Tozawa K, Oshima T, Okugawa T et al. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig Dis Sci 2014; 59 (8): 1885–90.
57. Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci 2008; 106 (3): 469–77.
________________________________________________
2. Maev I.V., Samsonov A.A., Andreev D.N. Gastropatii, indutsirovannye nesteroidnymi protivovospalitel'nymi sredstvami: patogeneticheski obosnovannye podkhody k profilaktike i terapii. Farmateka. 2016; 2: 49–54. [in Russian]
3. Tannenbaum H, Bombardier C, Davis P, Russel AS. An Evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006; 33: 140–57.
4. Lanas A, Chan FK. Peptic ulcer disease. Lancet 2017 Feb 23. pii: S0140-6736(16)32404-7.
5. Lanas A, Perez-Aisa MA, Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100 (8): 1685–93.
6. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it – can we stop it? Arch Intern Med 1986; 146 (6): 1075–6.
7. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013; 15 (Suppl. 3): S3.
8. Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol 2016; 10 (6): 723–33.
9. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82 (11): 1153–8.
10. Lanas Á, Carrera-Lasfuentes P, Arguedas Y et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13 (5): 906–12.e2.
11. Lewis SC, Langman MJ, Laporte JR et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54 (3): 320–6.
12. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46.
13. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382 (9894): 769–79.
14. Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol 2014; 12 (4): 398–413.
15. Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
16. DeRuiter J. Non-steroidal antiinflammatory drugs (NSAIDS). Principles of Drug Action 2002; 2: 1–25.
17. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-nflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 121–32.
18. Zidar N, Odar K, Glavac D et al. Cyclooxygenase in normal human tissues – is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? Cell Mol Med B 2009; 13 (9): 3753–63.
19. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996; 6 (3): 489–504.
20. Mitchell JA, Akarasereenont P, Thiemermann C et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90 (24): 11693–7.
21. Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci 2005; 50 (1): S16–S23.
22. Konturek SJ, Konturek PC, Pawlik T et al. Duodenal mucosal protection by bicarbonate secretion and its mechanisms. J Physiol Pharmacol 2004; 55: 5–17.
23. Svintsitskii A.S. NPVP gastroduodenopatii u bol'nykh osteoartrozom: osobennosti diagnostiki, profilaktiki i lecheniia. Nauchno-prakticheskaia revmatologiia. 2002; 3: 26–31. [in Russian]
24. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34 (6): 742–7.
25. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992; 16 (3): 227–40.
26. Andrews FJ, Malcontenti-Wilson C, O’Brien PE. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am J Physiol 1994; 266 (4, part 1): G657–G664.
27. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995; 109 (4): 1173–80.
28. Nasonov E.L., Karateev A.E. Porazheniia zheludka, sviazannye s priemom nesteroidnykh protivovospalitel'nykh preparatov (chast' I). Klin. med. 2000; 3: 4–9. [in Russian].
29. Fiorucci S, Antonelli E, Morelli A. Mechanism of non-steroidal anti- inflammatory drug-gastropathy. Digest Liver Dis 2001; 33 (Suppl. 2): S35.
30. Maev I.V., Samsonov A.A., Andreev D.N. Infektsiia Helicobacter pylori. M.: GEOTAR-Media, 2016. [in Russian].
31. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359 (9300): 14–22.
32. Lim YJ, Hong SJ. Helicobacter pylori infection in nonsteroidal anti-infl ammatory drug users. Korean J Gastroenterol 2014; 64 (2): 70–5.
33. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6–30.
34. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology, Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728–38.
35. Laine L. The role of proton pump inhibitors in NSAID – associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Dis 2003; 3 (4): S30–S39.
36. Micklewright R, Lane S, Linley W et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003; 17 (3): 321–32.
37. Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. Ther Clin Risk Management 2008; 4 (5): 983–97.
38. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086.
39. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343 (21): 1520–8.
40. Schwartz J, Dallob A, Larson P et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008; 48 (6): 745–54.
41. Chan F, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173–9.
42. Goldstein J, Eisen G, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 3–13.
43. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiology 2005; 71 (7–8): 461–70.
44. Nguyen A, Chaiton A. Cyclooxygenase (COX-2) selective inhibitors: any better than NSAIDs? Can Fam Physician 2001; 47: 1398–400.
45. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs – nice or necessary? Rev Gastroenterol Dis 2004; 4 (Suppl. 4): S33–S41.
46. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411e18.
47. Koch M. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol 1999; 31 (1): S54–S62.
48. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241–9.
49. Graham Y, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119 (4): 257–62.
50. Iinuma S, Naito Y, Yoshikawa T et al. In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci 1998; 43 (Suppl. 9): 35S–39S.
51. Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996; 41 (6): 1139–44.
52. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Exp Rev Gastroenterol Hepatol 2010; 4 (3): 261–70.
53. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci 2013; 58 (7): 1991–2000.
54. Kim JH, Park SH, Cho CS et al. Preventive efficacy and safety of rebamipid in NSAD-indused toxicity. Gut Liver 2014; 8 (4): 371–79.
55. Park SH, Cho CS, Lee OY et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr 2007; 40 (2): 148–55.
56. Tozawa K, Oshima T, Okugawa T et al. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig Dis Sci 2014; 59 (8): 1885–90.
57. Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci 2008; 106 (3): 469–77.
Авторы
И.В.Маев1, Д.Н.Андреев*1, Д.Т.Дичева1, Е.В.Жиляев2,3
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
3 АО «Европейский медицинский центр». 123104, Россия, Москва, Спиридоньевский пер., д. 5, стр. 1
*dna-mit8@mail.ru
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
3 European Medical Center. 123104, Russian Federation, Moscow, Spiridonevskii per., d. 5, str. 1
*dna-mit8@mail.ru
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
3 АО «Европейский медицинский центр». 123104, Россия, Москва, Спиридоньевский пер., д. 5, стр. 1
*dna-mit8@mail.ru
________________________________________________
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
3 European Medical Center. 123104, Russian Federation, Moscow, Spiridonevskii per., d. 5, str. 1
*dna-mit8@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.